Second-line chemotherapy with weekly oxaliplatin and high-dose 5-fluorouracil with folinic acid in metastatic colorectal carcinoma: A Hellenic Cooperative Oncology Group (HeCOG) phase II feasibility study

A phase II study of the modulation of 5-fluorouracil and folinic acid with high-dose infusional hydroxyurea in metastatic colorectal carcinoma

Annals of Oncology ◽

10.1023/a:1008330302535 ◽

1999 ◽

Vol 10 (8) ◽

pp. 981-983 ◽

Cited By ~ 5

Author(s):

K.J. O'Byrne ◽

P.A. Philip ◽

D.J. Propper ◽

I.P. Braybrooke ◽

M.P. Saunders ◽

...

Keyword(s):

Colorectal Carcinoma ◽

Folinic Acid ◽

Phase Ii ◽

Phase Ii Study ◽

High Dose ◽

Metastatic Colorectal Carcinoma

Second line chemotherapy for metastatic colorectal carcinoma

Oncology Reports ◽

10.3892/or.3.5.867 ◽

1996 ◽

Author(s):

V Gebbia ◽

A Testa ◽

G Cannata ◽

M Tirrito ◽

A Longo ◽

...

Keyword(s):

Colorectal Carcinoma ◽

Second Line ◽

Metastatic Colorectal Carcinoma ◽

Phase II study of oxaliplatin as second-line chemotherapy in endometrial carcinoma: A Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2006.03.043 ◽

2006 ◽

Vol 103 (2) ◽

pp. 523-526 ◽

Cited By ~ 30

Author(s):

Paula M. Fracasso ◽

John A. Blessing ◽

Kelly L. Molpus ◽

Lisa M. Adler ◽

Joel I. Sorosky ◽

...

Keyword(s):

Endometrial Carcinoma ◽

Phase Ii ◽

Phase Ii Study ◽

Gynecologic Oncology ◽

Second Line ◽

Oncology Group ◽

Oncology Group Study ◽

Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) Study

Gynecologic Oncology ◽

10.1016/j.ygyno.2003.11.023 ◽

2004 ◽

Vol 92 (2) ◽

pp. 644-647 ◽

Cited By ~ 117

Author(s):

Katherine Y Look ◽

Alan Sandler ◽

John A Blessing ◽

Joseph A Lucci ◽

Peter G Rose

Keyword(s):

Phase Ii ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Uterine Leiomyosarcoma ◽

Second Line ◽

Oncology Group ◽

5-Fluorouracil and High-Dose Folinic Acid as Second-Line Chemotherapy in Head and Neck Cancer

American Journal of Clinical Oncology ◽

10.1097/00000421-199002000-00001 ◽

1990 ◽

Vol 13 (1) ◽

pp. 1-3 ◽

Cited By ~ 7

Author(s):

Marco Merlano ◽

Almalina Bacigalupo ◽

Marco Benasso ◽

Andrea Grimaldi ◽

Salvatore Toma ◽

...

Keyword(s):

Head And Neck Cancer ◽

Head And Neck ◽

Folinic Acid ◽

Neck Cancer ◽

High Dose ◽

Second Line ◽

Oxaliplatin plus high-dose folinic acid and 5-fluorouracil i.v. bolus (OXAFAFU) versus irinotecan plus high-dose folinic acid and 5-fluorouracil i.v. bolus (IRIFAFU) in patients with metastatic colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase III trial

Annals of Oncology ◽

10.1093/annonc/mdi185 ◽

2005 ◽

Vol 16 (6) ◽

pp. 878-886 ◽

Cited By ~ 31

Author(s):

P. Comella ◽

B. Massidda ◽

G. Filippelli ◽

S. Palmeri ◽

D. Natale ◽

...

Keyword(s):

Colorectal Carcinoma ◽

Folinic Acid ◽

Southern Italy ◽

Phase Iii ◽

High Dose ◽

Oncology Group ◽

Metastatic Colorectal Carcinoma ◽

Phase Iii Trial

Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: A Phase II study of the Gynecologic Oncology Group

Gynecologic Oncology ◽

10.1016/j.ygyno.2008.03.009 ◽

2008 ◽

Vol 110 (1) ◽

pp. 65-70 ◽

Cited By ~ 31

Author(s):

David Scott Miller ◽

John A. Blessing ◽

Diane C. Bodurka ◽

Albert J. Bonebrake ◽

John O. Schorge

Keyword(s):

Phase Ii ◽

Phase Ii Study ◽

Gynecologic Oncology ◽

Second Line ◽

Oncology Group ◽

Recurrent Carcinoma ◽

A multicenter phase II study of pemetrexed as second-line chemotherapy for the treatment of hormone refractory prostate cancer (HRPC); Hoosier Oncology Group GU-0367

Journal of Clinical Oncology ◽

10.1200/jco.2008.26.15_suppl.16019 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 16019-16019 ◽

Cited By ~ 2

Author(s):

N. M. Hahn ◽

R. T. Zon ◽

T. Jones ◽

F. Ademuyiwa ◽

W. M. Dugan ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Hormone Refractory Prostate Cancer ◽

Second Line ◽

Oncology Group ◽

Multicenter Phase ◽

Hormone Refractory ◽

A phase II evaluation of flavopiridol as second-line chemotherapy of endometrial carcinoma: A Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2005.05.017 ◽

2005 ◽

Vol 98 (2) ◽

pp. 249-253 ◽

Cited By ~ 37

Author(s):

Edward C. Grendys ◽

John A. Blessing ◽

Robert Burger ◽

James Hoffman

Keyword(s):

Endometrial Carcinoma ◽

Phase Ii ◽

Gynecologic Oncology ◽

Second Line ◽

Oncology Group ◽

Oncology Group Study ◽

Faculty Opinions recommendation of Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1120032.576156 ◽

2008 ◽

Author(s):

Enrico Sartori

Keyword(s):

Phase Ii ◽

Phase Ii Study ◽

Gynecologic Oncology ◽

Second Line ◽

Oncology Group ◽

Recurrent Carcinoma ◽